Industry landscapes
The companies, capital and talent shaping healthtech in Melbourne. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
12 of 345 tracked companies have open roles.
54 of 345 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 84 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 41.7% of disclosed capital, while 84.3% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $10.53M | 24 | 6 |
| 2017 | $4.75M | 24 | 4 |
| 2018 | $21M | 21 | 6 |
| 2019 | $19.14M | 27 | 7 |
| 2020 | $60.14M | 30 | 8 |
| 2021 | $83.86M | 8 | 11 |
| 2022 | $54.19M | 7 | 8 |
| 2023 | $89.86M | 19 | 11 |
| 2024 | $12.13M | 14 | 6 |
| 2025 | $123.6M | 2 | 5 |
Share of all disclosed company funding.
100 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Gobi Partners and Horizons Ventures.
Backed by Point72 Ventures and Blackbird Ventures and others.
Backed by SGH and Cochlear and others.
Backed by National Reconstruction Fund and Brandon Capital.
Backed by Tenmile and Firetrail and others.
Backed by Headline and LocalGlobe and others.
Backed by VU Venture Partners and Artesian and others.
Backed by Cochlear and University of Melbourne and others.
Backed by King River and Perennial and others.
Backed by Cochlear and University of Melbourne and others.
Backed by Medical Research Commercialisation Fund and Yuuwa Capital.
The measured Australia identity-to-filing probe did not produce a qualifying designated legal or national-ID join: bare ticker overlaps lack a recorded ASX exchange designation and are not designated legal or national identifiers.
How the Melbourne companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
7 of the 345 companies on this page carry a measured traffic record (2%); these are the largest of those, by monthly visits. The median among them is 1,489,699 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| HotDochotdoc.com.au | 8,552,236 | 62 | 89.3% |
| eRx Script Exchangeerx.com.au | 5,798,568 | 31 | 98.9% |
| Clinikocliniko.com | 4,788,990 | 46 | 67% |
| fatsecretfatsecret.com | 1,489,699 | 67 | 53.3% |
| Halaxyhalaxy.com | 1,255,619 | 42 | 30.3% |
| Qoctorqoctor.com.au | 73,898 | 34 | 72.1% |
| Medmatemedmate.com.au | 58,931 | 33 | 75.5% |
Visits and authority are third-party web estimates, not company-reported figures.
53 of these companies (15.4%) publish at least one Android app — 81 apps in all, carrying 70.8M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Calorie Counter by fatsecretfatsecret | 62.8M | 4.5 | Health & Fitness |
| HotDocHotDoc | 3.9M | 4.1 | Medical |
| Feed Baby - Baby TrackerFeed Baby | 2.3M | 4.3 | Parenting |
| ForHealthHotDoc | 284.7K | 5 | Medical |
| Lyf App - Social That CaresLyf App | 277.2K | 3.7 | Social |
| Sicky: Medical CertificateSicky | 222.7K | — | Medical |
| Nerva: Gut-Brain TherapyMindset Health | 188.9K | 4.6 | Health & Fitness |
| SiSU Health Mobile Appsisu health group | 98.5K | — | Health & Fitness |
| Feed Baby Pro - Baby TrackerFeed Baby | 98.3K | 4.3 | Parenting |
| Partnered HealthHotDoc | 76.8K | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q2–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 18 | 65.6M | Calorie Counter by fatsecret 62.8M | |
| Fitness & Wellness Tech | 3 | 62.9M | Treat App 9.4K | |
| Healthcare Booking Platforms | 18 | 5M | HotDoc 3.9M | |
| Healthcare It | 57 | 4.7M | ForHealth 284.7K | |
| Mom & Baby Care | 2 | 2.4M | Feed Baby - Baby Tracker 2.3M | |
| Wearable Technology | 4 | 90.8K | Bladder Diary by iUFlow 72.8K | |
| Artificial Intelligence | 3 | 81K | Heidi 69.9K | |
| Enterprise Resource Planning | 2 | 75.2K | Operoo Central 74.5K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 53 of 81 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
7 companies hiring · $458.8M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Radoff and Torok, who with certain of their affiliates comprise the Radoff-JEC Group, are now offering $2.35 per share plus a contingent value right.
QuidelOrtho said this week that it has completed the acquisition of UK-based Lex Diagnostics for about $100 million in cash.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly‑owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc.
US-based drone logistics company Zipline has raised an additional $200 million, bringing its recent Series H funding round to $800 million.
Cortical Labs , a Melbourne-based deep tech company developing biological computing systems, secured an undisclosed investment in a round co-led by Horizon Ventures and 3C.
HotDoc goes from GP to PE as founder confirms sale to Potentia.
Epiminder raised $125m at $1.50 per share, giving it a market capitalisation of $325 million.
Empatica has acquired PKG Health to enhance its AI-enabled wearable technology with validated movement disorder algorithms.
Healthcare AI startup Heidi Health has raised $65 million in Series B funding led by billionaire Steve Cohen’s Point72
4DMedical previously secured a AUD 10 million strategic investment from Pro Medicus, a high‑profile medical imaging software firm.
Top 10 categories among 196 recorded events in the 24-month window.
5 companies with recorded IPO activity
IPO · ASX3 reports
IPO1 reports
IPO · Australian Securities Exchange2 reports
IPO · ASX1 reports
IPO · Nasdaq Global Market3 reports
7 tracked people moves
Appointment Non-Executive Director
Appointment Non-Executive Director
Appointment Chair of its board
Appointment Non-Executive Director
Appointment Chief Financial Officer
Appointment Non-Executive Director
Products, platforms and features in the recorded window
Delivery
2 recorded customer wins
Customer: regeneron pharmaceuticalsBiopharmaceutical
Customer: State government of Assam
8 recorded events
approved for saleU.S.
application accepted for approvalNational Health Authority (NMPA)
approval for investmentChina ODI
CRL issuedFDA
6 tracked suits
breach of fiduciary duties over tax benefit planCivil · Ongoing
Federal Securities Laws violationCivil · Filed
Reported company results in the recorded window.
Median across 54 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Radoff-JEC Group→Seer ↗ | Announced | 2026-04-24 | Not stated in snapshot |
| quidelortho→Lexdiagnostics ↗ | Completed | 2026-04-24 | $100.0M |
| potentia→HotDoc ↗ | Announced | 2026-02-18 | Not stated in snapshot |
| empatica→PKG Health ↗ | Announced | 2025-10-08 | Not stated in snapshot |
| Global Health→Medanta Holdings (MHPL) | 2025-03-18 | Not stated in snapshot | |
| sedna→Seer ↗ | Announced | 2025-03-05 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
0 postings in the preceding 12 months. The full 2-posting snapshot covers 1 employers.
No repeated job title is supported by this snapshot.
0 tracked postings mention remote work.
Top skills across 2 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| Global Health ↗ | 10,538 |
| Seer ↗ | 328 |
| Telix Pharma ↗ | 234 |
| 4DMedical ↗ | 141 |
| Austcohealthcare ↗ | 102 |
| CurveBeam AI ↗ | 83 |
| Nutromics ↗ | 52 |
| Zipline ↗ | 52 |
191 founders and chief executives across 143 companies.
Blackbird, ex-Fraser's GAMSAT. University of Melbourne MD 2017 & BSc 2013
The University of Melbourne, Australian-American Fulbright Commission, University of Melbourne…
Medtech Innovator, ex-Australia Post, ex-Ibm, University of Melbourne - Melbourne Business School, 2016
Ex-Imaging Sciences. BIT, Patna, The Ohio State University
Salient Medical, ex-EndoStim, Nexstim, McKinsey. Monash University BS 1986, Harvard University PhD 1993
Ex-Envato, SLI Systems.University of Canterbury BE 2011
Ex-Grant Thornton, Co-Founder Covet. Monash University 2018
Cortical Labs, ex-Clinicloud, ex-Peninsula Health, Johns hopkins school of medicine, 2012
Rhodes Scholarship Trust, ex-Irabina Autism Services, The Boston Consulting Group, The Royal Children's Hospital. Monash University Bachelors 2008…
Ex-Director Pro-Active Industries Pty Ltd. Southern Cross University Associate Degree in Law 1997
Atmo Biosciences, ex-Planet Innovation, ex-Northside Montessori School, Australian Institute of Company Directors, 2014
University of Melbourne MBBS 2006, New School MFA 2012
28 profiles with education records.
4 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
36,595 articles in the measured 12-month window.
Healthtech coverage tagged Melbourne · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 10,001 |
| 2021Q3 | 11,070 |
| 2021Q4 | 9,756 |
| 2022Q1 | 14,518 |
| 2022Q2 | 9,221 |
| 2022Q3 | 10,185 |
| 2022Q4 | 18,235 |
| 2023Q1 | 22,445 |
| 2023Q2 | 9,539 |
| 2023Q3 | 11,362 |
| 2023Q4 | 10,642 |
| 2024Q1 | 12,569 |
| 2024Q2 | 11,229 |
| 2024Q3 | 9,736 |
| 2024Q4 | 13,763 |
| 2025Q1 | 16,293 |
| 2025Q2 | 7,568 |
| 2025Q3 | 10,906 |
| 2025Q4 | 8,585 |
| 2026Q1 | 10,568 |
Article volume measures coverage, not market sales.
294 recorded company events across 20 companies; percentages use that event total.
Healthtech coverage tagged Melbourne · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Australia comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,005 | 1,939 | 107% |
| domestic robots | 3,109 | 43 | 7130% |
| toy robots | 3,082 | 29 | 10528% |
| ashes moments | 1,191 | 772 | 54% |
| angel investors | 1,017 | 370 | 175% |
| overseas study | 971 | 685 | 42% |
| ashes urn | 897 | 392 | 129% |
| ashes records | 857 | 403 | 113% |
| semester abroad | 817 | 522 | 57% |
| ashes venues | 809 | 429 | 89% |
| test cricket | 5,971 | 11,546 | -48% |
| test innings | 4,543 | 8,864 | -49% |
| 5-day cricket | 3,717 | 7,764 | -52% |
| odi cricket | 2,923 | 6,168 | -53% |
| limited overs cricket | 2,793 | 6,143 | -55% |
Australia comparison coverage
territories, disputed islands, test cricket
27.4% critical · 18.9% positivetest cricket, test innings, odi world cup
31.7% critical · 42.2% positivecore inflation rate, inflation outlook, aflw premiership
31.6% critical · 46.7% positiveHealthtech coverage tagged Melbourne. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Researchers examine obstacles to building resilient health systems and the factors that undermine system stability.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Papers highlight difficulties in discovering and repurposing drugs for multifactorial diseases.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Studies identify practical and acceptance issues that limit the rollout of eHealth and digital transformation.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Research points to logistical, regulatory, and quality‑assessment challenges in delivering remote care.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Works discuss limits of molecular diagnostics, biomarker reliability, and resistance in personalized cancer treatment.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Analyses focus on safety concerns, risk assessment, and evolving regulatory frameworks for devices and wearables.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Investigations assess how COVID‑19 amplified usage pressures and highlighted gaps in remote clinical services.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Authors urge careful evaluation of telehealth’s impact on patient outcomes and satisfaction before broad adoption.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Papers caution about technical, workflow, and equity challenges when deploying e‑health tools in diverse settings.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Research stresses the need for robust validation of biomarkers and predictive models in drug development.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Studies highlight variable efficacy, user engagement, and ethical issues in digital psychological therapies.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Analyses reveal clinician resistance, workflow disruption, and equity gaps during pandemic‑driven telemedicine expansion.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Works point to gaps in awareness, data sharing, and practical uptake of personalized oncology approaches.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Authors discuss transparency, bias, and accountability concerns surrounding AI‑driven precision medicine.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Research proposes models and design methods to improve the clinical usability of digital health technologies.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Papers showcase computational screening and docking as promising routes to accelerate therapeutic identification.
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Studies highlight how molecular docking and chemical space exploration can streamline target‑focused drug design.
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Research identifies remote delivery of physical therapy and palliative services as emerging high‑impact applications.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Works explore leveraging genetic heterogeneity to tailor treatments for complex diseases like Alzheimer’s and cancer.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Studies demonstrate how connected wearables can support remote patient monitoring and expand access to care.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Research focuses on circulating tumor cell analysis and molecular markers to refine personalized oncology strategies.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 36.8% |
| Problem-identifying | 29.0% | 9.7% |
| Descriptive | 18.8% | 17.5% |
| Breakthrough | 12.7% | 26.7% |
| Cautionary | 6.4% | 4.4% |
| Comparative | 2.5% | 4.0% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 3 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗